Novel CD4+ Donor Lymphocyte Therapy Shows Promising Remission Rates in High-Risk Myeloid Malignancie | Blood Cancers Today
CD4+ MMUDLI treatment achieved complete remission rates of more than 50% in treatment-refractory myelodysplastic syndrome.
Related Articles
Cancer of the Brain and Other Nervous System – Cancer Stat Facts
Brain and Other Nervous System Cancer statistics
SEQUOIA Extended Follow-Up Supports Initial Findings in CLL/SLL | Blood Cancers Today
After five years of follow-up in the phase 3 SEQUOIA study, first-line zanubrutinib treatment continues to demonstrate an improvement in progression-free survival in CLL versus…
Development of Patient-Derived Lymphoma Tumoroids for Studying Follicular Lymphoma | Blood Cancers Today
Follicular lymphoma demonstrates a strong interplay with its tumor microenvironment, influencing disease progression and therapy resistance.
Fertility Counseling and Preservation in Patients With NHL | Blood Cancers Today
Researchers say barriers such as time constraints and financial limitations complicate fertility counseling and preservation for patients with lymphoma.
Allogeneic Hematopoietic Stem Cell Transplantation in R/R B-Cell Non-Hodgkin Lymphoma | Blood Cancers Today
While CAR-T cell therapy has emerged as a transformative salvage option for around 40% of patients, long-term data on allo-HSCT remain sparse, research shows.
Breastcancer.org – Breast Cancer Information and Support
We are your go-to resource for clear, reliable, accurate, and up-to-date breast cancer information as well as community support.
Potential Benefits of Selinexor for CAR-T Therapies | Blood Cancers Today
Drs. Rossi and Khouri discuss two presentations on the effects of selinexor exposure on CAR-T outcomes in multiple myeloma.
Pacritinib and Momelotinib Display Positive Real-World Impact on Anemia and Transfusion Needs in Myelofibrosis
Pacritinib and momelotinib both demonstrated favorable real-world effects on anemia and transfusion requirements among patients with myelofibrosis.
